139 related articles for article (PubMed ID: 37522680)
1. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
Güneş E; Güneş M
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients.
Kırkgöz T; Eltan M; Kaygusuz SB; Yavaş Abalı Z; Helvacıoğlu D; Seven Menevşe T; Gürpınar Tosun B; Güran T; Bereket A; Turan S
J Clin Res Pediatr Endocrinol; 2022 Mar; 14(1):10-16. PubMed ID: 34355879
[TBL] [Abstract][Full Text] [Related]
3. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
5. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
6. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).
Kawaguchi Y; Sawa J; Hamai C; Nishimura Y; Kumeda Y
J Diabetes Investig; 2019 Nov; 10(6):1527-1536. PubMed ID: 30868726
[TBL] [Abstract][Full Text] [Related]
8. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
9. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
Onishi Y; Yamada K; Zacho J; Ekelund J; Iwamoto Y
J Diabetes Investig; 2017 Mar; 8(2):210-217. PubMed ID: 27560769
[TBL] [Abstract][Full Text] [Related]
12. The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy.
Altay FP; Farzaliyeva A; İyidir ÖT; Bozkuş Y; Kırnap NG; Kut A; Nar A; Tütüncü NB
Endocr Metab Immune Disord Drug Targets; 2023; 23(6):826-831. PubMed ID: 36424790
[TBL] [Abstract][Full Text] [Related]
13. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
[TBL] [Abstract][Full Text] [Related]
15. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
Mehta R; Chen R; Hirose T; John M; Kok A; Lehmann R; Unnikrishnan AG; Yavuz DG; Fulcher G
Diabetes Obes Metab; 2020 Nov; 22(11):1961-1975. PubMed ID: 32618405
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
17. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
[TBL] [Abstract][Full Text] [Related]
18. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study.
Mohamed M; Lim SC; Mumtaz M; Uppal S; Mukherjee D; Kassim MSM; Sreedharan S; Doraiswamy AM; Chong KM; Tat LY; Nordin SB; Giek JLH; Hussein Z; Kadir KA; Lau BK; Chan SP
J ASEAN Fed Endocr Soc; 2023; 38(1):37-44. PubMed ID: 37252419
[TBL] [Abstract][Full Text] [Related]
19. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
[TBL] [Abstract][Full Text] [Related]
20. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
